ALMA and Herschel reveal that AGN and main-sequence galaxies have different star formation rate distributions

Using deep Herschel and ALMA observations, we investigate the star formation rate (SFR) distributions of X-ray AGN host galaxies at 0.5<z<1.5 and 1.5<z<4, comparing them to that of normal, star-forming (i.e., "main-sequence", or MS) galaxies. We find 34-55 per cent of AGNs have SFRs at least a factor of two below that of the average MS galaxy, compared to ~15 per cent of all MS galaxies, suggesting significantly different SFR distributions. Indeed, when both are modelled as log-normal distributions, the mass and redshift-normalised SFR distributions of AGNs are roughly twice as broad, and peak ~0.4 dex lower, than that of MS galaxies. However, like MS galaxies, the normalised SFR distribution of AGNs appears not to evolve with redshift. Despite AGNs and MS galaxies having different SFR distributions, the linear-mean SFR of AGNs derived from our distributions is remarkably consistent with that of MS galaxies, and thus with previous results derived from stacked Herschel data. This apparent contradiction is due to the linear-mean SFR being biased by bright outliers, and thus does not necessarily represent a true characterisation of the typical SFR of AGNs

X-Ray Spectral Constraints for z ≈ 2 Massive Galaxies: The Identification of Reflection-dominated Active Galactic Nuclei

We use the 4 Ms Chandra Deep Field-South (CDF-S) survey to place direct constraints on the ubiquity of z 2 heavily obscured active galactic nuclei (AGNs) in K 10 keV observatories. On the basis of these analyses, we estimate the space density for typical (intrinsic X-ray luminosities of L 2-10 keV 1043 erg s–1) heavily obscured and Compton-thick AGNs at z 2. Our space-density constraints are conservative lower limits but they are already consistent with the range of predictions from X-ray background models

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362